JCI Insight · 2017 · 387 citations · 47 references
MedicineImmunologyOncologyCancer ImmunologyCellular MetabolismTumor ImmunologyCancer ImmunotherapyCancer MetabolismImmune Cell MetabolismMetabolic ReprogrammingMitochondrial MetabolismRenal Cell CarcinomaCd8+ Tumor-infiltrating LymphocytesGlycolysis In Cancer MetabolismGlycolytic PathwaysTumor Cell MetabolismTumor MetabolismTumor Microenvironment EffectsTumor Suppressor LossTumor Suppressor Pathways
Cancer cells can inhibit effector T cells (Teff) through both immunomodulatory receptors and the impact of cancer metabolism on the tumor microenvironment. Indeed, Teff require high rates of glucose metabolism, and consumption of essential nutrients or generation of waste products by tumor cells may impede essential T cell metabolic pathways. Clear cell renal cell carcinoma (ccRCC) is characterized by loss of the tumor suppressor von Hippel-Lindau (VHL) and altered cancer cell metabolism. Here, we assessed how ccRCC influences the metabolism and activation of primary patient ccRCC tumor infiltrating lymphocytes (TIL). CD8 TIL were abundant in ccRCC, but they were phenotypically distinct and both functionally and metabolically impaired. ccRCC CD8 TIL were unable to efficiently uptake glucose or perform glycolysis and had small, fragmented mitochondria that were hyperpolarized and generated large amounts of ROS. Elevated ROS was associated with downregulated mitochondrial SOD2. CD8 T cells with hyperpolarized mitochondria were also visible in the blood of ccRCC patients. Importantly, provision of pyruvate to bypass glycolytic defects or scavengers to neutralize mitochondrial ROS could partially restore TIL activation. Thus, strategies to improve metabolic function of ccRCC CD8 TIL may promote the immune response to ccRCC.
47
Ethan Cerami, Jianjiong Gao, Uğur Doğrusöz et al. · Cancer Discovery · 2012 · 18.4K citations · Full text
Medicine, Bioinformatics, Oncology +15
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo et al. · Science · 2006 · 6.5K citations
Medicine, Immunology, Oncology +17
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Comprehensive molecular characterization of clear cell renal cell carcinoma
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih‐Hao Chang, Jing Qiu, David O’Sullivan et al. · Cell · 2015 · 3.2K citations · Full text
Medicine, Cancer Biology, Oncology +16